Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11376 - 11400 of 11565 in total
SGN-30 is an engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared to on normal cells. SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase...
Investigational
Matched Description: … antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a ... SGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials. …
Sage oil is extracted from sage or Salvia officinalis, the herb commonly used for culinary purposes. Salvia officinalis is a common sage and a member of the genus Salvia, that includes aromatic and perennial plants with flowers. Essential oil has been traditionally used in medicine for the relief of pain...
Nutraceutical
Matched Description: … *Salvia officinalis* is a common sage and a member of the genus *Salvia*, that includes aromatic and …
Pagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone. It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with...
Investigational
Matched Description: … It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which …
Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of typhoid fever. The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of S. typhi. It is being developed by AVANT Immunotherapeutics, Inc.
Investigational
Matched Description: … Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against Salmonella typhi< …
SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important...
Investigational
Matched Description: … SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug …
Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors. It is extracted through lysis of the plasma membrane of platelets. Because white cell antigens are low in prepared lysate, there is a minimized likelihood...
Investigational
Matched Description: … Because white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses …
Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines. Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis.[A19218,A19219,A19220]
Investigational
Matched Description: … Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. …
Serrapeptase is a proteolytic enzyme preparation used concomitantly with an antibiotic in osteoarticular infections. Serratiopeptidase is under investigation in clinical trial NCT02493179 (Efficacy Evaluation of the (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery).
Investigational
Matched Description: … Serrapeptase is a proteolytic enzyme preparation used concomitantly with an antibiotic in osteoarticular …
Pinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)).
Investigational
Matched Description: … Pinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin …
Diosmetin is an O-methylated flavone and the aglycone part of the flavonoid glycosides diosmin that occurs naturally in citrus fruits . Pharmacologically, diosmetin is reported to exhibit anticancer, antimicrobial, antioxidant, oestrogenic and anti-inflamatory activities . It also acts as a weak TrkB receptor agonist .
Experimental
Matched Description: … It also acts as a weak TrkB receptor agonist [A27230]. …
Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)).
Investigational
Matched Description: … Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration …
PCLX-001 is a first-in-kind N-Myristoyltransferase (NMT) inhibitor being developed by Pacylex Pharmaceuticals (https://pacylex.com). Current studies have shown that PCLX-001 works differently than other known cancer drugs and has high activity and positive results in breast, lung, bladder and pancreas cancers.
Investigational
Matched Description: … PCLX-001 is a first-in-kind N-Myristoyltransferase (NMT) inhibitor being developed by [Pacylex Pharmaceuticals …
QRX-411 is a first-in-class RNA-based oligonucleotide designed to restore wild-type USH2A mRNA, leading to the production of the functional USH2A protein. It addresses the underlying cause of Usher syndrome due to the c.7595-2144A&gt;G mutation in the USH2A gene.
Investigational
Matched Description: … QRX-411 is a first-in-class RNA-based oligonucleotide designed to restore wild-type USH2A mRNA, leading …
3-Carbamoyl-1-beta-D-ribofuranosyl pyridinium hydroxide-5'phosphate, inner salt. A nucleotide in which the nitrogenous base, nicotinamide, is in beta-N-glycosidic linkage with the C-1 position of D-ribose. Synonyms: Nicotinamide Ribonucleotide; NMN. [PubChem]
Experimental
Matched Description: … A nucleotide in which the nitrogenous base, nicotinamide, is in beta-N-glycosidic linkage with the C- …
BF-37 for the treatment of atopic dermatitis and/or psoriasis. The active ingredient in BF-37 is Riluzole, applied in a topical formulation, which is believed to correct the imbalances of the immune system that cause atopic dermatitis or psoriasis.
Investigational
Matched Description: … The active ingredient in BF-37 is Riluzole, applied in a topical formulation, which is believed to correct …
SB-269970 is an experimental drug developed by GlaxoSmithKline. In the studies performed with this agent, it has been suggested that SB-269970 acts either as a selective antagonist or inverse agonist of the serotonin receptor 7 (5-HT7).[A31816,A31817]
Investigational
Matched Description: … In the studies performed with this agent, it has been suggested that SB-269970 acts either as a selective …
Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways. S-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.
Experimental
Investigational
Matched Description: … Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared …
Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated for the treatment of advanced non-small cell lung cancer (NSCLC).
Investigational
Matched Description: … Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically …
Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals. Jaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating Patients With MDS With MF or MDS/MPN With MF.).
Investigational
Matched Description: … Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals. …
NSI-566 is a stem cell therapy consisting of human spinal cord-derived neural stem cells. Developed by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).
Investigational
Matched Description: … NSI-566 is a stem cell therapy consisting of human spinal cord-derived neural stem cells. …
TG100801 is a topically applied kinase inhibitor in macular degeneration patients. It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological hallmarks of AMD and other back of the eye...
Investigational
Matched Description: … TG100801 is a topically applied kinase inhibitor in macular degeneration patients. …
Ramosetron is a serotonin 5-HT3 receptor antagonist commonly employed to treat nausea and vomiting, in addition to certain diarrheal conditions. It is believed to have higher potency and longer antiemetic action than other 1st generation 5-HT3 antagonists such as ondansetron. Currently, ramosetron is only approved for use Japan and in...
Investigational
Matched Description: … Ramosetron is a _serotonin 5-HT3 receptor antagonist_ commonly employed to treat nausea and vomiting, …
RG2417 is a proprietary formulation of uridine, a biological compound essential for the synthesis of DNA and RNA, the basic hereditary material found in all cells, and numerous other factors essential for cell metabolism. Uridine is synthesized by the mitochondria, the power plant of the human cell responsible for energy...
Investigational
Matched Description: … RG2417 is a proprietary formulation of uridine, a biological compound essential for the synthesis of …
MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood of adults and children. Research on AFP suggests that it may play a role in modulating the immune system of...
Investigational
Matched Description: … MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein ... Research on AFP suggests that it may play a role in modulating the immune system of the mother in order …
Displaying drugs 11376 - 11400 of 11565 in total